The role of amino acid signaling in pathogenesis of chronic kidney disease

Mol Cell Biochem. 2025 Dec 5. doi: 10.1007/s11010-025-05447-0. Online ahead of print.ABSTRACTChronic kidney disease (CKD) is a comprehensive disease characterized by renal injury and decreased renal function, which can lead to increased cardiovascular and all cause mortality rates, seriously affecti

S Siya Yan

Challenges in Revascularization in Patients With Systemic Lupus Erythematosus

JACC Case Rep. 2025 Dec 4:106251. doi: 10.1016/j.jaccas.2025.106251. Online ahead of print.ABSTRACTBACKGROUND: Systemic lupus erythematosus (SLE) markedly increases cardiovascular risk through inflammation and thrombophilia, which may be further intensified by antiphospholipid syndrome (APS).CASE SU

R Rodrigo Uriel Palacios

Anticoagulants in hematologic malignancies: what is the data?

Hematology Am Soc Hematol Educ Program. 2025 Dec 5;2025(1):61-71. doi: 10.1182/hematology.2025000688.ABSTRACTHematologic malignancies are associated with an increased risk of venous thromboembolism (VTE) with aggressive lymphomas and multiple myeloma exhibiting the highest VTE incidence. The perform

R Ruah Alyamany

The aging hemophilia patient

Hematology Am Soc Hematol Educ Program. 2025 Dec 5;2025(1):674-681. doi: 10.1182/hematology.2025000773.ABSTRACTAdvances in the development of safe and effective treatments for hemophilia over the past century have significantly increased the life expectancy of persons with hemophilia (PwH). As a res

M Magdalena Lewandowska

Can I stop my treatment, doctor? Is MRD-guided therapy ready for prime time?

Hematology Am Soc Hematol Educ Program. 2025 Dec 5;2025(1):645-651. doi: 10.1182/hematology.2025000761.ABSTRACTIndefinite maintenance therapy, typically with lenalidomide, remains a standard of care for patients with multiple myeloma, largely based on studies that demonstrated improved progression-f

B Benjamin A Derman

How to approach the high-risk myeloma from induction through relapse?

Hematology Am Soc Hematol Educ Program. 2025 Dec 5;2025(1):652-658. doi: 10.1182/hematology.2025000762.ABSTRACTDespite the enormous progress made in the treatment of multiple myeloma (MM) with various treatment choices in frontline and relapse settings, treatment of high-risk (HR)MM remains a therap

K Katja C Weisel

Transplant in myeloma: what is its role?

Hematology Am Soc Hematol Educ Program. 2025 Dec 5;2025(1):401-404. doi: 10.1182/hematology.2025000730.ABSTRACTQuadruplet induction regimens containing anti-CD38 monoclonal antibodies in combination with a triplet backbone are providing deeper and more durable responses in newly diagnosed multiple m

C Cesar Rodriguez

What is the best induction for myeloma for the fit patient?

Hematology Am Soc Hematol Educ Program. 2025 Dec 5;2025(1):405-411. doi: 10.1182/hematology.2025000731.ABSTRACTMultiple myeloma (MM), a neoplasm of plasma cells, is the second most common hematologic malignancy. With treatment advances, patients are living longer. However, the disease remains incura

N Nishi Nilesh Shah

Choosing the optimal maintenance strategy in multiple myeloma

Hematology Am Soc Hematol Educ Program. 2025 Dec 5;2025(1):412-423. doi: 10.1182/hematology.2025000732.ABSTRACTWhile lenalidomide has been the established standard of care for maintenance after autologous stem cell transplantation in newly diagnosed multiple myeloma, risk-adapted maintenance strateg

B Benjamin Puliafito

Implementation failure: thromboprophylaxis in ambulatory patients with cancer

Hematology Am Soc Hematol Educ Program. 2025 Dec 5;2025(1):72-79. doi: 10.1182/hematology.2025000689.ABSTRACTVenous thromboembolism (VTE) is a frequent complication in patients with cancer, especially those receiving systemic therapy in the ambulatory setting. Despite being a largely preventable con

E Elena Butera

Demystifying the diagnosis and management of ICUS, CHIP, and CCUS

Hematology Am Soc Hematol Educ Program. 2025 Dec 5;2025(1):682-690. doi: 10.1182/hematology.2025000766.ABSTRACTPrecursor states such as clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance, carry distinct risks for progression to myeloid neoplasms

Z Zhuoer Xie

Thalassemia and hypercoagulability

Hematology Am Soc Hematol Educ Program. 2025 Dec 5;2025(1):285-290. doi: 10.1182/hematology.2025000716.ABSTRACTAlthough the management of β-thalassemia has improved significantly, patients still suffer from many complications, including thrombotic events. A hypercoagulable state has been demonstrate

M Maria Domenica Cappellini